The field of single-cell transcriptomics is growing rapidly, driven by the need to understand cellular heterogeneity better. As it expands, researchers are increasingly challenged by the complexity of the technologies and data involved. One of the most critical and often overlooked challenges is tissue dissociation. Unlike bulk RNA-seq, which provides an averaged gene expression profile across thousands of cells, scRNA-seq requires a precise, customized approach at every step. Different tissues, species and models, such as organoids, make applying a one-size-fits-all isolation protocol impossible. In addition, many researchers lack a background in computational biology or coding, which limits their ability to extract insight from complex data. ROKIT Genomics addresses these challenges by stepping into the researcher’s shoes. Drawing on published methods and pilot studies, the team identifies the most effective strategies to ensure optimal tissue dissociation, even in the most intricate biological systems. Its flexible multiplexing strategies, (including antibody-, probe-, and non-labeling-based methods) allow multiple samples to be processed simultaneously with a single reagent set, significantly improving cost-efficiency and throughput. Supporting a wide range of platforms, including 10x Genomics, BD Rhapsody and MobiDrop, it adapts to the unique needs of every project. As a designated reference lab for BD Biosciences, the team is also among the first to deploy and validate emerging applications, ensuring clients benefit from the latest advancements in the field. Its support often extends to project design, troubleshooting and manuscript preparation. The pre-analysis consultation ensures that clients receive the most relevant results..

Every year, the medical field witnesses promising discoveries—new molecules, novel biomarkers, and breakthrough technologies that promise earlier diagnoses and more effective treatments. Despite the hope they carry, many of these discoveries never make it to the patients who need them most. They remain confined to research papers, circulating in academic circles, but falling short of delivering practical value in the clinic. Physicians continue to face unanswered questions, laboratories accumulate unused findings, and patients wait for tools that could transform their care. Dunwill Medical was founded to break this cycle. The company’s mission is to ensure that the enormous potential of biomarker research is translated into real-world diagnostic products that physicians and patients can trust. By positioning itself at the intersection of clinical practice, cutting-edge science, and industrialization expertise, Dunwill ensures that ideas born in the laboratory are transformed into solutions that directly improve outcomes at the bedside. “Our best R&D capability is not to create a fancy idea,” says Sofia Wen, founder and CEO. “It is to take a doctor’s idea and bring it to life as a dependable IVD product.” Innovation Rooted in Clinical Practice The cornerstone of Dunwill’s approach is what the company describes as its “Stronger together” model. Its innovation process begins in the hospital, at the point of patient care. The first step in every project is not a new piece of technology or an abstract research idea, but the real challenges that physicians and surgeons encounter daily. If a surgeon struggles with unclear diagnostic results or if a physician faces limitations in current testing methods, that pain point becomes the starting point for Dunwill’s work. By partnering with clinicians, listening to their needs, and involving them from the earliest stages, the company ensures that the developed solutions are immediately relevant, practical, and actionable. This model is compelling in China, where translational medical research has advanced internationally. Chinese hospitals and research institutes are increasingly recognized as leaders in basic and applied medical science. Dunwill leverages this ecosystem by collaborating with some of the nation’s most respected hospitals and clinical experts. Through these collaborations, the company can identify unmet clinical needs, connect them with emerging biomarker discoveries, and then apply its proven industrialization capabilities to transform those discoveries into finished diagnostic products..